Panelists agreed that treatments requiring a washout period prior to CAR-T cell infusion should include allo-HSCT (off immunosuppression and absence of GvHD), high-dose chemotherapy, systemic corticosteroids, PIs, IMiDs, donor lymphocyte infusion, and anti-CD38 monoclonal antibodies. Here, CD38 is linked to graft versus host disease.